AGA Family of Websites:

GI Clinical Trialists Bootcamp

We launched a 10-week bootcamp for GIs interested in becoming clinical trial investigators who identify with a group underrepresented in medicine (URiM), treat URiM patients, or practice in an area with limited access to clinical trial sites. 

We’re diversifying clinical trials from the top down.

Apply for AGA’s GI Clinical Trialists Bootcamp: IBD (next cohort April-June 2024). AGA’s free 10-week virtual and on-demand training program will equip GI clinicians with the knowledge and skills for navigating clinical trials through expert-led sessions, collaborative discussions, networking and real-world examples.

Our goal is to increase the number and diversity of gastroenterologists involved in clinical trials and ultimately increase the participation of underrepresented or underserved patients in clinical trials. Bootcamp participants will join an exclusive cohort with access to sessions taught by leading experts in IBD clinical trials. 

See eligibility, learn more about the program, and hear from past bootcamp participants below.

Apply now

Applications for the next GI Clinical Trialists Bootcamp cohort (April-June 2024) are due by March 13, 2024.

The GI Clinical Trialist Bootcamp is part of a larger AGA initiative to strengthen, diversify and connect the clinical trials workforce within gastroenterology. We are starting with a focus on IBD clinical trials due to the increasing challenges of recruiting diverse patients, particularly in the U.S.  

This free, 10-week training program includes comprehensive training for gastroenterologists through live virtual and on-demand education. Each cohort will be limited to 10-15 participants to maximize interactions with program faculty and your fellow participants. The curriculum covers key issues in clinical trial investigation, including but not limited to investigator responsibilities, regulatory requirements, clinical trial operations, protocol development, informed consent and medical ethics. 

Ten to fifteen individuals will be selected to participate in each cohort of this program. AGA membership is not required to apply for this program. Additional requirements may be found below: 

Applicants must be physicians who treat IBD, from any type of practice, who fulfill at least one of the following criteria: 

  • Identify with a racial and/or ethnic group that is underrepresented in medicine (URiM): African Americans or Blacks, Native Alaskans, Native Americans, U.S. Pacific Islanders and individuals of Hispanic origin.
  • Serve a diverse patient population, particularly patients who identify with URiM racial and/or ethnic groups.  
  • Work in a practice setting with little to no existing infrastructure for clinical trials. 
  • Practice in a geographic area without easy access to established clinical trial sites. 

Hear from bootcamp graduates

Congratulations Bianca Islam, MD, PhD, Jana Al Hashash, MD, MS, and Elie Al Kazzi, MD, MPH, three bootcamp participants who received AGA’s GI Clinical Trialists Seed Grants to build a clinical trial infrastructure at their institution. Watch this quick video to learn more about their work. 

Steering Committee

Picture of Maria T. Abreu, MD, AGAF

Maria T. Abreu, MD, AGAF

University of Miami Miller School of Medicine 

Picture of Anita Afzali, MD, MPH, MHCM, FACG, AGAF

Anita Afzali, MD, MPH, MHCM, FACG, AGAF

The Ohio State University Wexner Medical Center

Picture of Leonard K. Baidoo, MD, FACG, AGAF

Leonard K. Baidoo, MD, FACG, AGAF

University of Tennessee Health Science Center

Picture of Brigid S. Boland, MD

Brigid S. Boland, MD

University of California, San Diego

Picture of Adam S. Cheifetz, MD

Adam S. Cheifetz, MD

Beth Israel Deaconess Medical Center

Picture of Andres J. Yarur, MD

Andres J. Yarur, MD

Cedar-Sinai Medical Center 

The current program is supported by an independent educational grant from Bristol Myers Squibb Company and Janssen Biotech, Inc.

The program was originally established through independent educational grants from AbbVie Inc.; Amgen; Bristol Myers Squibb Company; Genentech, a member of the Roche Group; Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC; and Takeda Pharmaceuticals U.S.A., Inc., and a quality improvement grant from Pfizer Inc.